Introduction {#s1}
============

The pregnancy-associated complication preeclampsia is a leading cause of maternal and fetal morbidity and mortality. Approximately 3% of all pregnant women in populations of European descent are affected by preeclampsia ([@GAR014C52]). In severe cases of preeclampsia, the only effective treatment is delivery, irrespective of gestational age. The classical clinical manifestations of preeclampsia are elevated blood pressure and proteinuria. The etiology is complex and like in other common complex disorders both genetic and environmental factors influence the risk of developing the disease. Genetic factors are suggested to be responsible for \>50% of the liability to preeclampsia ([@GAR014C53]; [@GAR014C40]), and several candidate genes have been studied. However, the results are inconsistent and specific causative genes involved in preeclampsia still remain to be identified ([@GAR014C8]; [@GAR014C51]; [@GAR014C13]; [@GAR014C10]; [@GAR014C42]; [@GAR014C45]).

A recent animal study put forward the suggestion that deficiency in catechol-*O*-methyltransferase (COMT) is associated with preeclampsia ([@GAR014C32]). COMT is a key enzyme in the degradation of both catecholamines and estrogens ([@GAR014C14]). High- and low-activity variants of COMT, due to single base changes, have been discovered ([@GAR014C15]). One polymorphism with functional implications is a non-synonymous *G* to *A* base change (rs4680; NM_000754.2), the *COMT Val108/158Met* polymorphism. This polymorphism results in a substitution of the amino acid valine for methionine at codon 108 and 158 in the soluble and membrane bound isoforms of COMT, respectively. The Met(*A*)-allele of this polymorphism is associated with a 3- to 4-fold decrease in COMT enzyme activity ([@GAR014C37]), and several clinical conditions such as pain perception ([@GAR014C66]; [@GAR014C15]), psychiatric disorders ([@GAR014C65]; [@GAR014C3]; [@GAR014C48]), hypertension ([@GAR014C26]; [@GAR014C23], [@GAR014C24]; [@GAR014C2]) and heart disease ([@GAR014C18]; [@GAR014C23], [@GAR014C24]; [@GAR014C63]) have been reported to be associated with this base change.

Inspired by Kanasaki *et al.*\'s hypothesis that COMT deficiency is associated with preeclampsia, we examined the potential role of high and low activity haplotypes in the central region of *COMT*. The functional *COMT Val108/158Met* polymorphism and an additional single-nucleotide polymorphism (SNP; rs6269) were genotyped to account for the three major haplotypes observed in the central region of *COMT* in populations of European descent ([@GAR014C21]; [@GAR014C15]).

Materials and Methods {#s2}
=====================

The HUNT population {#s2a}
-------------------

All women subjected to genotyping were retrospectively identified from the second Nord-Trøndelag Health Study (HUNT2) ([@GAR014C29]). Preeclampsia was defined as the onset of persistent hypertension (exceeding 140/90 mmHg), in combination with proteinuria (exceeding 300 mg/l per day) after 20 weeks gestation. Women with preeclamptic (cases) and non-preeclamptic (controls) singleton pregnancies in the HUNT2 cohort were identified by linking the HUNT database to the Medical Birth Registry of Norway (MBRN) ([@GAR014C41]). The inhabitants of Nord-Trøndelag county are well suited for genetic studies due to ethnic homogeneity (\<3% non-Caucasians) ([@GAR014C29], [@GAR014C30]). The HUNT2 preeclampsia cohort is described in detail elsewhere ([@GAR014C41]; [@GAR014C19]).

### Clinical characterization of the HUNT2 preeclampsia cohort {#s2a1}

Cases registered with one preeclamptic pregnancy were defined as non-recurrent, and cases with more than one preeclamptic pregnancy were defined as recurrent. The non-recurrent preeclampsia group also included women with only one registered pregnancy in the MBRN. Preterm delivery was defined as delivery before 37 weeks ([@GAR014C67]). Small for gestational age (SGA) was defined as an infant with a birthweight ≤2 standard deviations (SDs) below the expected weight for gestational age and sex, corresponding to the 2.5 percentile ([@GAR014C69]). For assessment of metabolic syndrome, an International Diabetes Federation (IDF) proxy definition \[waist circumference ≥80 cm plus any two of high density lipid (HDL) cholesterol \<1.29, treatment for hypertension or blood pressure ≥130/≥85 mm Hg, diabetes diagnosed after age of 30\] ([@GAR014C68]) was used, as fasting blood glucose was not available for all the individuals in the study cohort. Using the IDF proxy definition in a cross-sectional analysis of 10 206 HUNT2 participants, Hildrum *et al.* showed that there was no differences in the prevalence of metabolic syndrome between fasting and non-fasting groups ([@GAR014C68]).

SNP genotyping {#s2b}
--------------

DNA for genotyping was extracted from blood samples stored in the HUNT biobank, as described elsewhere ([@GAR014C41]). Applied Biosystems' TaqMan genotyping assays (Applied Biosystems, Foster City, CA, USA) were selected to genotype the rs4680 (*Val108/158Met*) and rs6269 SNPs using 5 ng of genomic DNA from each of the case and control samples. The assays were performed on an Applied Biosystems 7900HT Fast Real-Time PCR System at HUNT biobank and sample genotypes were interrogated using the integrated 7900HT system data analysis software. The genotyping procedure has been validated at HUNT biobank by LightCycler (Roche Diagnostics Scandinavia AB, Stockholm, Sweden) hybridization probe genotyping and DNA sequencing of rs4680.

Haplotype analysis {#s2c}
------------------

Haplotypes were predicted from genotype information from each individual using the computer program Phase (<http://stephenslab.uchicago.edu/home.html>) ([@GAR014C60]; [@GAR014C59]). Only individuals with both SNPs successfully genotyped were included in the haplotype analysis (*n*= 3036; *n*~controls~= 2029, *n*~cases~= 1007; *n*~non-recurrent~= 888, *n*~recurrent~= 119). The frequency of the haplotypes was also calculated based on this number of individuals.

Only a few common *COMT* haplotypes are observed in populations of European descent ([@GAR014C21]; [@GAR014C15]), and three major *COMT* haplotypes accounting for ∼96% of all detected haplotypes in the coding region determine the COMT activity in humans ([@GAR014C15]). Figure [1](#GAR014F1){ref-type="fig"} shows these three major haplotypes that are demonstrated to constitute four central SNPs (rs6269, rs4633, rs4818 and rs4680) ([@GAR014C15]). These three haplotypes are associated with very different COMT enzyme activities ([@GAR014C43]), and have also been demonstrated to be associated with variation in sensitivity to experimental pain. They were therefore designated as low pain sensitivity (LPS), average pain sensitivity (APS) and high pain sensitivity (HPS) ([@GAR014C15]). There is an inverse correlation between pain sensitivity and COMT activity, meaning that the LPS haplotype represents the high *COMT* activity haplotype, whereas the HPS represents the low *COMT* activity haplotype and the APS represents the intermediate *COMT* activity haplotype. Figure 1Haplotypes in the central region of the *COMT* gene. \[(Figure modified from [@GAR014C1])\]. A total of four central SNPs in the *COMT* gene have been demonstrated to combine into three common haplotypes ([@GAR014C15]) which have been associated with variation in COMT enzyme activity ([@GAR014C43]). The two SNPs marked with a pale blue rectangle, rs6269 and rs4680, in combination differentiate between the three common activity haplotypes ([@GAR014C25]) and were the ones genotyped in the present study. Frequencies for the haplotypes detected shown in this figure are consistent with previous findings and the frequencies observed by Diatchenko *et al.* are shown in brackets.

In this study, the genotyped SNPs (rs4680 and rs6269) were selected based on the observation that only two of the central four SNPs were needed to tag the variation in a Norwegian sample set ([@GAR014C25]). It was observed that there is strong pair wise linkage disequilibrium (LD) with almost perfect correlation (*r*^2^\> 0.97) between rs6269--rs4818 and rs4633--rs4680, and that the rs6269 SNP tags the high *COMT* activity haplotype ([@GAR014C25]).

Statistical analysis {#s2d}
--------------------

### Clinical characterisation {#s2d1}

The software package SPSS 16.0 for Windows was used to compute descriptive statistics such as mean and SD. *P*-values were computed based on *t*-test statistics for normally distributed variables. Non-parametrical methods (χ^2^) were used for categorical variables. The non-recurrent and recurrent preeclampsia groups were analyzed separately. Each preeclamptic group was compared with the non-preeclamptic group. Multivariate logistic regression was used to model preeclampsia as the (dichotomous) dependent variable against maternal age. A threshold of α = 0.05 was set for statistical significance of all computed analyses.

### SNP and haplotype association analysis {#s2d2}

Concordance with Hardy--Weinberg proportions was tested using a *χ*^2^ goodness-of-fit statistic. The SNP association analyses for the *Val108/158Met* (rs4680) and rs6269 SNPs and haplotype association analyses for the four possible haplotypes (Fig. [1](#GAR014F1){ref-type="fig"}) were carried out in PASW Statistics version 17 using a Pearson\'s *χ*^2^ statistic. The SNPs and haplotypes were analyzed separately for the subgroups of preeclamptic women (non-recurrent and recurrent) against non-preeclamptic control women. An additive (*A* allele frequency versus *G* allele frequency) genetic model was used for the SNP association analysis. For the haplotype association analyses, we tested whether carrying one of the four possible haplotypes was associated with disease state. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. A threshold of α = 0.05 was set for statistical significance of all computed analyses.

Ethics {#s2e}
------

The study was approved by the Regional Committee for Medical Research Ethics, the National Data Inspectorate and The Directorate of Health and Social Welfare in Norway.

Results {#s3}
=======

Statistical power analysis {#s3a}
--------------------------

Using a relevant range of minor allele frequencies (30--50%) \[National Center for Biotechnology Information (NCBI) SNP database\], *a priori* power calculations *ad modum* Lalouel and Rhorwasser ([@GAR014C33]) for the genotyped SNPs demonstrated 80% power to detect an effect size (OR) difference of 1.25 for the non-recurrent group (*n*= 1003) and 1.65--1.75 for the subgroup of women with recurrent preeclampsia (*n*= 136).

Clinical characterization {#s3b}
-------------------------

The original HUNT2 preeclampsia cohort (1139 cases and 2269 controls) was used when performing the clinical characterisation ([@GAR014C41]; [@GAR014C19]). Mean follow-up time from index pregnancy recorded in MBRN to inclusion in the present study was 25 ± 10 years. Gestational age and birthweight differed between the neonates in preeclamptic and non-preeclamptic pregnancies, the preeclamptic women had a higher risk of preterm delivery, and of delivering a SGA neonate (Table [I](#GAR014TB1){ref-type="table"}, *P*\< 0.001). Metabolic syndrome was evaluated by data from the HUNT2 study and was higher in the case groups when compared with controls (Table [I](#GAR014TB1){ref-type="table"}, *P*\< 0.001). After adjusting for maternal age, the differences in clinical phenotype between case and control groups remained significant (Table [I](#GAR014TB1){ref-type="table"}, *P*\< 0.001). Table IClinical characteristics of the HUNT2 preeclampsia case/control cohort.Preeclampsia (non-recurrent, *n*= 1003)Preeclampsia (recurrent^a^, *n*= 136)Control (*n*= 2269)Maternal age at index pregnancy (years)27 ± 6\*25 ± 525 ± 5Gestational age (days)275 ± 22\*271 ± 20\*282 ± 18Birthweight (g)3.238 ± 837\*3.040 ± 846\*3.483 ± 592SGA^b^147 (15)\*26 (20)\*87 (4)Preterm birth^c^132 (14)\*29 (22)\*114 (5)Maternal age at inclusion in HUNT240 ± 1137 ± 9\*40 ± 11Metabolic syndrome^d^163 (16)\*30 (22)\*212 (9)[^2][^3][^4][^5][^6][^7][^8]

We also observed clinical differences between the group of women with recurrent and non-recurrent preeclampsia (Table [I](#GAR014TB1){ref-type="table"}). The women with recurrent preeclampsia delivered earlier (*P*= 0.018) and had a higher prevalence of preterm birth (22%) compared with the women with non-recurrent preeclampsia (16%; *P*\< 0.01). The neonates from the recurrent preeclamptic pregnancies had a lower birthweight (adjusted for gestational age, *P*= 0.055), but the seemingly different prevalence of SGA (20 versus 15% recurrent versus non-recurrent) was not statistically significant (*P*= 0.2). The *P*-values were adjusted for maternal age. The group of women with recurrent preeclampsia also had a higher prevalence of metabolic syndrome at inclusion in the HUNT2 study compared with the women with non-recurrent preeclampsia when adjusting for age at inclusion (*P*= 0.019).

*COMT* genotyping and association analysis {#s3c}
------------------------------------------

DNA samples were available for 1135 women registered with preeclamptic pregnancies and 2262 controls. We observed a high genotyping success rate for the rs4680 and rs6269 SNPs in both cases (94%) and controls (95%), and both SNPs conformed to Hardy--Weinberg proportions (*P*\> 0.05). Approximately 10% of our samples were genotyped on both the TaqMan and the LightCycler genotyping system with a concordance of 99%. No association between the two studied *COMT* SNPs and non-recurrent preeclampsia was observed in our Norwegian cohort (Table [II](#GAR014TB2){ref-type="table"}). However, a significant overrepresentation of the wild type allele (*Val* (*G*)), not the low activity allele (*Met* (*A*)), of the *Val108/158Met* polymorphism (rs4680) was observed in the group of women with recurrent preeclampsia (*P*= 0.047, OR = 0.77, CI 0.6--1.0) (Table [II](#GAR014TB2){ref-type="table"}). No association was observed between rs6269 and recurrent preeclampsia (Table [II](#GAR014TB2){ref-type="table"}). Table IIDistribution of COMT genotypes and alleles in the HUNT2 preeclampsia case/control cohort.SNPGenotype (NN)Preeclampsia non-recurrentPreeclampsia recurrentControlORCIAllele (N)*n* (proportion of total)*n* (proportion of total)*n* (proportion of total)rs4680 (*Val108/158Met*)GG174 (0.18)36 (0.28)412 (0.19)AG461 (0.48)60 (0.46)1097 (0.50)AA335 (0.35)35 (0.27)678 (0.31)A (*Met*)1131 (0.58)130 (0.50)2453 (0.56)1.1^a^1.0--1.2^a^G (*Val*)809 (0.42)132 (0.50)1921 (0.44)0.8^b,^\*0.6--1.0^b^rs6269AA361 (0.39)47 (0.39)771 (0.37)GA412 (0.45)52 (0.43)1035 (0.49)GG143 (0.16)23 (0.19)289 (0.14)A1134 (0.62)146 (0.60)2577 (0.62)1.0^a^0.9--1.1^a^G698 (0.38)98 (0.40)1613 (0.39)0.9^b^0.7--1.2^b^[^9][^10][^11][^12]

The three common *COMT* haplotypes as well as the less frequent *G*-*A* (rs6269--rs4680) haplotype were detected in our Norwegian cohort (Table [III](#GAR014TB3){ref-type="table"} and Fig. [1](#GAR014F1){ref-type="fig"}). The frequencies of the three common haplotypes in our cohort are shown in Fig. [1](#GAR014F1){ref-type="fig"} and are consistent with frequencies observed in other studies (Fig. [1](#GAR014F1){ref-type="fig"}) ([@GAR014C15]; [@GAR014C49]; [@GAR014C25]). The less frequent *G--A* haplotype observed in our cohort is likely to be the *G--C--C--A* haplotype observed by Diatchenko *et al.* ([@GAR014C15]), as this is the only haplotype with *G--A* at the two SNPs genotyped in the current study. We found that carrying the low *COMT* activity haplotype was significantly associated with recurrent preeclampsia (*P*= 0.018, OR = 1.8, CI 1.1--2.8) (Table [III](#GAR014TB3){ref-type="table"}). The non-recurrent preeclampsia group did not show association with any of the haplotypes. Table IIICOMT haplotypes in the HUNT2 preeclampsia case/control cohort.Haplotypers6269 --rs4680 (N-N)Preeclampsia non-recurrent (proportion)Preeclampsia recurrent (proportion)Control (proportion)ORCI1 (high activity)G--G516 (0.58)72 (0.61)1237 (0.61)0.9^a^0.8--1.0^a^1.0^b^0.7--1.4^b^2 (intermediate activity)A--A710 (0.80)87 (0.73)1627 (0.80)1.0^a^0.8--1.2^a^0.7^b^0.4--1.0^b^3 (low activity)A--G110 (0.12)25 (0.21)263 (0.13)1.0^a^0.8--1.2^a^1.8^b^\*1.1--2.8^b^4 (unknown activity)G--A30 (0.03)2 (0.02)58 (0.03)1.2^a^0.8--1.9^a^0.6^b^0.1--2.4^b^[^13][^14][^15][^16][^17]

Discussion {#s4}
==========

Growing evidence supports the role of COMT in human pregnancy. The COMT enzyme is reported to be active in both placenta ([@GAR014C6]) and decidua ([@GAR014C9]), and expression in human fetal membranes has recently been reported ([@GAR014C27]). Decreased placental COMT activity was first reported to be associated with hypertension in pregnancy ([@GAR014C6]). More recently, reduced placental COMT protein expression has been observed in women with severe preeclampsia ([@GAR014C32]). On the basis of the latter observation, together with observations from studying *COMT* knockout mice, *COMT* was introduced as a preeclampsia susceptibility gene ([@GAR014C32]). The *Comt−/−* mice developed a preeclampsia-like syndrome, with elevated blood pressure, albuminiuria, glomerular changes, placental thrombosis, and hypoxia and preterm birth. However, administration of 2-methoxyestradiol (2-ME), a natural estrogen metabolite produced by COMT, to pregnant *Comt−/−* mice ameliorated the preeclampsia-like symptoms ([@GAR014C32]). It was suggested that genetic variation within the *COMT* gene could be an explanation for disruption of COMT and 2-ME in preeclamptic women ([@GAR014C32]).

SNPs in the *COMT* gene have been shown to significantly affect enzyme activity ([@GAR014C37]; [@GAR014C15]; [@GAR014C44]). It was therefore reasonable to hypothesize that SNPs in this gene are associated with preeclampsia pathogenesis. Recently, the *Val108/158Met* polymorphism was shown to be associated with preeclampsia in a small Korean population cohort of 164 preeclamptic and 182 normotensive patients ([@GAR014C36]). However, it has become clear that the *Val108/158Met* polymorphism alone is not likely to account for the variation of COMT enzyme activity. Four central SNPs (rs6269, rs4633, rs4818 and rs4680) in the *COMT* gene combine to form three common haplotypes ([@GAR014C15]), and these are associated with varying levels of COMT enzyme activity ([@GAR014C43]) (Fig. [1](#GAR014F1){ref-type="fig"}). The fact that the wild type *Val108/158* (*G*) allele is present in both the high and low *COMT* activity haplotypes ([@GAR014C15]) demonstrates the importance of studying haplotypes rather than single SNPs. We therefore performed haplotype analysis to see whether any of the three common haplotypes (Fig. [1](#GAR014F1){ref-type="fig"}) were associated with preeclampsia. We found that the low *COMT* activity haplotype, with a 58-fold reduced enzyme activity ([@GAR014C44]), was significantly associated with recurrent preeclampsia (*P*= 0.018), with an OR of 1.8 (CI 1.1--2.8) for carrying this haplotype. Consistent with other studies, our group of women with recurrent preeclampsia showed the highest risk of preterm labor, low fetal birthweight and the highest risk of later life cardiovascular disease (assessed as metabolic syndrome) ([@GAR014C58]; [@GAR014C47]; [@GAR014C38]). Therefore, our findings support the hypothesis that lower maternal COMT enzyme activity predisposes to severe preeclampsia.

Angiogenesis, the formation of new blood vessels, is a central process in development of both preeclampsia and cardiovascular diseases. Alterations in angiogenesis during early pregnancy contribute to incomplete remodeling of uterine spiral arteries and abnormal placental vascular development ([@GAR014C51]). Decreased COMT activity and subsequent reduced levels of estrogen metabolites, such as 2-ME, may impair vascular health in several ways. ([@GAR014C34]; [@GAR014C5]; [@GAR014C17]; [@GAR014C16]). It has been demonstrated that 2-ME has antiangiogenic effects ([@GAR014C20]), suppressing hypoxia-inducible factor-1α (HIF-1α), which plays an essential role in angiogenesis. This transcription factor is responsible for the induction of genes that facilitate the adaption and survival of cells during low-oxygen levels ([@GAR014C64]; [@GAR014C55]), including soluble fms-like tyrosine kinase 1. 2-ME has recently been suggested to be an important co-stimulator together with low-oxygen levels for induction of the invasiveness of trophoblasts ([@GAR014C35]). Thus, it has been suggested that 2-ME plays a role in maintaining placental homeostasis ([@GAR014C31]). Disturbances in COMT and 2-ME homeostasis and regulation may cause placental pathology in different ways at different stages of the pregnancy. A premature increase in 2-ME has been hypothesized to disturb hypoxia-driven trophoblast invasion and vascular remodeling and therefore contribute to preeclampsia pathogenesis ([@GAR014C35]). In late pregnancy, decreased COMT activity, thus lower levels of 2-ME and decreased inhibition of HIF-1α could potentially cause vascular pathology and inflammatory activation ([@GAR014C4]). Studies examining the expression and activity of the COMT enzyme throughout pregnancy are warranted to clarify the role of COMT/2-ME at different stages of the pregnancy.

Acting as a pro-oxidant, 2-ME has direct involvement in redox-regulated signaling ([@GAR014C4]), a possible shared disease mechanism between preeclampsia and cardiovascular diseases. Furthermore, the COMT enzyme is also important for homocysteine metabolism, a known cardiovascular risk factor ([@GAR014C56]). A combination of high serum homocysteine levels and the low activity *Val108/158* allele conferred increased risk (hazard risk ratio of 2.94) of acute coronary events in middle-aged men from eastern Finland ([@GAR014C63]). A similar mechanism has been suggested for preeclampsia ([@GAR014C56]). Such epigenetic effects might explain the diverging results found in both genetic studies concerning *COMT* and epidemiologic studies concerning vitamin B and homocysteine levels ([@GAR014C50]; [@GAR014C54]; [@GAR014C18]; [@GAR014C39]; [@GAR014C26]; [@GAR014C23], [@GAR014C24]; [@GAR014C63]; [@GAR014C2]; [@GAR014C28]; [@GAR014C22]; [@GAR014C44]; [@GAR014C46]; [@GAR014C12]; [@GAR014C36]). In summary, the *COMT* gene may be a candidate gene for the genetic liability possibly shared between preeclampsia and cardiovascular disease. Altered COMT enzyme activity and 2-ME production is likely to be of great importance in the development of both preeclampsia and cardiovascular diseases ([@GAR014C16]).

Based on research showing that due to strong pair wise LD between rs6269--rs4818 and rs4633--rs4680, two of these central four SNPs were considered to be sufficient to tag the variation in a Norwegian population ([@GAR014C25]). In the present study, the two SNPs (rs6269 and rs4680) were selected in order to represent three major haplotypes and a fourth less frequent haplotype (Fig. [1](#GAR014F1){ref-type="fig"}) in the central region of COMT. However, we do acknowledge that the multiple SNPs within the *COMT* gene give rise to a multitude of possible haplotype combinations, where minor differences between haplotypes may have profound effects on the COMT activity. To further investigate the role of genetic variation affecting COMT activity, one should extend the haplotype analysis to include the entire *COMT* gene. Only then can the 'true' effect of the high, intermediate and low activity haplotypes examined in the present study be controlled for. This can be done by looking at how these haplotypes are combined with the different haplotypes of flanking haploblocks. However, this will require very large study samples in order to account for the multitude of possible diplotype combinations ([@GAR014C1]).

The major *COMT* haplotypes differ with respect to mRNA secondary structure ([@GAR014C15]; [@GAR014C43]). The low *COMT* activity haplotype has been suggested to have notable functional consequences due to an RNA folding structure substantially deviating from the structure of the most frequent and older high *COMT* activity haplotype ([@GAR014C43]). Reduced enzymatic activity corresponding to the low *COMT* activity haplotype has been shown to be paralleled by reduced protein levels ([@GAR014C43]). Differences in the local secondary structure of mRNA are likely to result in differences in protein translation efficiency ([@GAR014C43]). The observation that the minor allele of an SNP (rs2097603) located in the promoter region of the membrane bound form of *COMT* producing a 1.5-fold reduction in lymphocyte COMT activity independent of the Val158Met allele supports this hypothesis ([@GAR014C11]). Another study found that a haplotype consisting of two non-coding SNPs (rs737865 in intron 1 and rs165599 in the 3′ untranslated region) reduced expression of COMT mRNA ([@GAR014C7]). The effect of the minor allele of three minor SNPs (rs6267, rs74062 and rs8192488) linked to the low COMT activity haplotype was recently studied. However, none of these minor SNPs significantly altered COMT RNA abundance, protein expression or enzymatic activity ([@GAR014C44]). A haplotype consisting of the minor alleles of rs737865 and rs4818 in the low activity haplotype are associated with increased thermal threshold variance, implicating a role for additional unobserved functional polymorphisms in the gene ([@GAR014C57]). Furthermore, it has been suggested that effects of the intermediate and low activity haplotypes might be modified by epistatic interactions (i) occurring at gene loci nearby COMT or (ii) with mutations located in convergent molecular pathways ([@GAR014C44]). Thorough re-sequencing of the COMT gene and impinging regions in order to identify additional SNPs would be of great interest. In addition, seven different mRNA splice variants exist for the *COMT* gene, which potentially exacerbates the complexity of COMT in biological mechanisms ([@GAR014C62]). Finally, in future studies it would also be of great interest to look at the fetal contribution since placental COMT is likely to be of importance.

Our total preeclampsia cohort was selected based on registry data and is therefore likely to represent a broad continuum of pathogenesis, ranging from mild preeclampsia to severe preeclampsia with both maternal and fetal complications. In the present study, we demonstrated significant association between the low activity *COMT* haplotype and recurrent preeclampsia, but not non-recurrent preeclampsia. A possible explanation for this might be that the recurrent preeclampsia group represents an 'end tail' or extreme subgroup of the continuum, with a greater power to detect genetic variation underlying disease development ([@GAR014C61]). Our result may suggest that this group, although smaller, has a greater power to detect genetic variation underlying disease development. Follow up studies in larger collections are warranted.

The aim of this study was to examine if *COMT* activity haplotypes observed in the Norwegian population were associated with preeclampsia. The two SNPs genotyped represent the four possible haplotypes that were independently tested. Since the outcomes of the tests performed for the four haplotypes are expected to be highly dependent, we have chosen not to include a conservative Bonferroni correction (dividing the *P*-value threshold with the number of tests performed, 0.05/4 = 0.0125). Using a conservative Bonferroni correction to adjust the *P*-value threshold due to testing two preeclampsia subgroups to 0.025 (0.05/2), the *P*-value for association between the recurrent preeclampsia group and the low activity haploype would still yield a significant result (*P*= 0.018). Although the evidence presented is not strong, our observation that a low *COMT* activity haplotype is associated with recurrent preeclampsia is consistent with other studies reporting low COMT protein expression ([@GAR014C31]) and enzyme activity ([@GAR014C6]) in preeclampsia. Larger studies are needed to further elucidate the hypothesis that genetic variation within the *COMT* gene could be an explanation for disruption of COMT and 2-ME homeostasis in preeclamptic women.

In conclusion, the available evidence makes *COMT* a likely and interesting candidate gene for preeclampsia development. The present study demonstrates that a low *COMT* activity haplotype contributes to the genetic liability of recurrent preeclampsia in our Norwegian HUNT2 cohort. Nonetheless, further genetic and functional studies are needed to validate our finding and clarify the role of the COMT enzyme in preeclampsia pathogenesis. Studies examining the expression and activity of the COMT enzyme throughout pregnancy are warranted.
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